Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ C4496238!4496238!25871387     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2015 ; 6 (11): 9551-63 Nephropedia Template TP {{tp|p=25871387|t=2015. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma |pdf=|usr=}}{{25871387}} gab.com Text Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25871387 #FOAvip Here we found that serum levels of thioredoxin were increased in patients with hepatocellular carcinoma (HCC). The optimum diagnostic cutoff for thioredoxin was 20.5 ng/mL (area under curve [AUC] 0.946 [95% CI 0.923?0.969] in the training cohort; 0.941 [0.918?0.963] in the validation cohort). High serum concentrations of thioredoxin differentiated HCC from chronic liver diseases and cirrhosis (0.901 [0.875?0.923] in the training cohort; 0.906 [0.870?0.925] in the validation cohort). Furthermore, a higher proportion of patients with very early HCC had positive results for thioredoxin than for alpha-Fetoprotein (AFP) (73.7% VS.31.6%; P < 0.0001). Among AFP-negative patients with very early HCC, 18 (69.2%) of 26 had positive thioredoxin results. Our results indicate that serum thioredoxin complements measurement of AFP in the diagnosis of HCC, especially in very early disease. Combined model (thioredoxin and AFP) showed a significantly greater discriminatory ability as compared with those markers alone. Twit Text FOAVip Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25871387 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25871387 #FOAvip English Wikipedia <ref>{{Cite pmid|25871387}}</ref> Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma #MMPMID25871387 Li J; Cheng ZJ; Liu Y; Yan ZL; Wang K; Wu D; Wan XY; Xia Y; Lau WY; Wu MC; Shen F Oncotarget 2015[Apr]; 6 (11): 9551-63 PMID25871387show ga Here we found that serum levels of thioredoxin were increased in patients with hepatocellular carcinoma (HCC). The optimum diagnostic cutoff for thioredoxin was 20.5 ng/mL (area under curve [AUC] 0.946 [95% CI 0.923?0.969] in the training cohort; 0.941 [0.918?0.963] in the validation cohort). High serum concentrations of thioredoxin differentiated HCC from chronic liver diseases and cirrhosis (0.901 [0.875?0.923] in the training cohort; 0.906 [0.870?0.925] in the validation cohort). Furthermore, a higher proportion of patients with very early HCC had positive results for thioredoxin than for alpha-Fetoprotein (AFP) (73.7% VS.31.6%; P < 0.0001). Among AFP-negative patients with very early HCC, 18 (69.2%) of 26 had positive thioredoxin results. Our results indicate that serum thioredoxin complements measurement of AFP in the diagnosis of HCC, especially in very early disease. Combined model (thioredoxin and AFP) showed a significantly greater discriminatory ability as compared with those markers alone. äSerum thioredoxin is a diagnostic marker for hepatocellular carcinoma (epmc).pdf DeepDyve Pubget Overpricing